NCT04227249Not yet recruiting
3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer
Three-year Recurrence Free Survival in Patients With Ultra-low-risk Endometrial Cancer Who do Not Undergo Lymph Node dissEction
Source: ClinicalTrials.gov · Last updated 14 Jan 2020 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To verify the safety of omission of lymph node dissection in ultra-low-risk endometrial cancer (KGOG criteria), we examine the survival of women with ultra-low-risk endometrial cancer who do not undergo lymph node dissection
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 153 (estimated)
- First submitted
- 2 Jan 2020
- Start date
- 1 Apr 2020
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Endometrial cancer
- NCT number
- NCT04227249
What you commit to
- Study type: Observational
- Planned participants: 153
- From 1 Apr 2020 to the primary completion date, 31 Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous hysterectomy
- previous therapy for endometrial cancer
Other illness
- other cancer within 5 yr
Who the study is looking for
- endometrioid type
- anticipated surgery omitting lymph node dissection for endometrial cancer
- pelvis MRI, CA125 - satisfying KGOG criteria
- no distant metastasis
- age 19 or more
Age in the registry: 19 years to - · Sex: Female
This page is information, not medical advice. Discuss any trial with your doctor.